CA2984621C - Histone deacetylase inhibitors and compositions and methods of use thereof - Google Patents

Histone deacetylase inhibitors and compositions and methods of use thereof Download PDF

Info

Publication number
CA2984621C
CA2984621C CA2984621A CA2984621A CA2984621C CA 2984621 C CA2984621 C CA 2984621C CA 2984621 A CA2984621 A CA 2984621A CA 2984621 A CA2984621 A CA 2984621A CA 2984621 C CA2984621 C CA 2984621C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
alkyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2984621A
Other languages
English (en)
French (fr)
Other versions
CA2984621A1 (en
Inventor
Celia Dominguez
Michel C. Maillard
Perla Breccia
Alan F. HAUGHAN
Rebecca E. Jarvis
Christopher A. LUCKHURST
Elizabeth A. Saville-Stones
Andrew J. STOTT
Amanda Van De Poel
Michael Wall
Grant Wishart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation Inc
Original Assignee
CHDI Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation Inc filed Critical CHDI Foundation Inc
Publication of CA2984621A1 publication Critical patent/CA2984621A1/en
Application granted granted Critical
Publication of CA2984621C publication Critical patent/CA2984621C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CA2984621A 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof Active CA2984621C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158379P 2015-05-07 2015-05-07
US62/158,379 2015-05-07
PCT/US2016/031329 WO2016179550A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2984621A1 CA2984621A1 (en) 2016-11-10
CA2984621C true CA2984621C (en) 2023-09-26

Family

ID=57218066

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2984621A Active CA2984621C (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Country Status (12)

Country Link
US (2) US10047073B2 (https=)
EP (1) EP3291809B1 (https=)
JP (1) JP6782255B2 (https=)
KR (1) KR20180002730A (https=)
CN (1) CN107735087B (https=)
AU (1) AU2016256917B2 (https=)
BR (1) BR112017023710B1 (https=)
CA (1) CA2984621C (https=)
EA (1) EA035592B1 (https=)
IL (1) IL255449B2 (https=)
MX (1) MX379817B (https=)
WO (1) WO2016179550A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016256917B2 (en) * 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX378983B (es) 2015-05-07 2025-03-10 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
WO2017211650A1 (en) * 2016-06-09 2017-12-14 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
BR112019001229B1 (pt) * 2016-07-22 2022-11-16 Syngenta Participations Ag Composto derivado de oxadiazol, composição agroquímica compreendendo o mesmo, método para controlar ou impedir infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto como fungicida
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
WO2019219464A1 (en) 2018-05-15 2019-11-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
KR102052844B1 (ko) 2019-01-31 2019-12-05 주식회사 아이스크림에듀 학습 분석 방법 및 시스템
KR102009034B1 (ko) 2019-01-31 2019-08-08 주식회사 아이스크림에듀 학습 분석을 기초로 정보를 제공하는 방법 및 시스템
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
KR102232343B1 (ko) 2019-12-11 2021-03-26 주식회사 아이스크림에듀 인공지능 기반 맞춤형 학습 방법 및 시스템
KR102191672B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 학습 분석 및 인공지능 기반 맞춤형 학습 방법 및 시스템
KR102191671B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 소셜 러닝 및 e포트폴리오 기반 맞춤형 학습 방법 및 시스템
KR102197752B1 (ko) 2019-12-20 2021-01-04 주식회사 아이스크림에듀 맞춤형 자동 문항 생성을 통한 인공지능 기반 학습 방법 및 시스템
KR102191670B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 문제은행 및 지식맵 기반 맞춤형 학습 방법 및 시스템
KR102258234B1 (ko) 2020-02-27 2021-05-31 주식회사 아이스크림에듀 인공지능 가정교사 인터페이스가 적용된 맞춤형 학습 방법 및 시스템
KR102258235B1 (ko) 2020-02-27 2021-05-31 주식회사 아이스크림에듀 실감 콘텐츠가 적용된 인공지능 기반의 맞춤형 학습 방법 및 시스템
KR102232344B1 (ko) 2020-02-27 2021-03-26 주식회사 아이스크림에듀 빅데이터 및 인공지능 기반의 맞춤형 학습 방법 및 시스템
CN111190006A (zh) * 2020-03-09 2020-05-22 上海市东方医院(同济大学附属东方医院) 组蛋白去乙酰化酶6在制备用于评估维持性腹膜透析患者腹膜功能的标志物中的用途
KR102222533B1 (ko) 2020-06-25 2021-03-05 주식회사 아이스크림미디어 고정형 웹 콘텐츠를 반응형 콘텐츠로 자동 변환하는 시스템 및 그 제어방법
KR20230049675A (ko) * 2020-08-07 2023-04-13 이탈파마코 에스.피.에이. 신규한 옥사디아졸-기반 선택적 hdac6 억제제
KR102248960B1 (ko) 2020-08-19 2021-05-07 주식회사 아이스크림에듀 인공지능 학습 플랫폼을 이용한 비즈니스 방법 및 시스템
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑hdac6抑制劑及其用途
CN117430513A (zh) * 2023-10-27 2024-01-23 中昊(大连)化工研究设计院有限公司 环丙基胺的合成新方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828171B1 (en) * 2004-12-10 2014-03-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Heterocycle derivatives as histone deacetylase (hdac) inhibitors
GB0427138D0 (en) * 2004-12-10 2005-01-12 Angeletti P Ist Richerche Bio Therapeutic compounds
US8981084B2 (en) * 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
EA201490228A1 (ru) * 2011-07-08 2014-08-29 Новартис Аг Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
BR112014012815A8 (pt) 2011-11-28 2017-06-20 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
KR20150000882A (ko) * 2012-04-05 2015-01-05 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법
AU2016256917B2 (en) * 2015-05-07 2021-08-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
MX378983B (es) 2015-05-07 2025-03-10 Chdi Foundation Inc Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos.
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
JP6491393B2 (ja) 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物

Also Published As

Publication number Publication date
HK1252489A1 (zh) 2019-05-24
CN107735087B (zh) 2021-09-03
AU2016256917B2 (en) 2021-08-26
EP3291809A4 (en) 2018-10-03
AU2016256917A1 (en) 2017-11-23
EP3291809A1 (en) 2018-03-14
US20160333001A1 (en) 2016-11-17
WO2016179550A1 (en) 2016-11-10
EP3291809B1 (en) 2021-08-25
IL255449B2 (en) 2023-07-01
IL255449B1 (en) 2023-03-01
BR112017023710B1 (pt) 2023-03-07
KR20180002730A (ko) 2018-01-08
CA2984621A1 (en) 2016-11-10
BR112017023710A2 (pt) 2018-07-31
JP2018515492A (ja) 2018-06-14
US20190185463A1 (en) 2019-06-20
IL255449A0 (en) 2017-12-31
EA201792255A1 (ru) 2018-06-29
MX2017014299A (es) 2018-08-09
US10047073B2 (en) 2018-08-14
EA035592B1 (ru) 2020-07-13
JP6782255B2 (ja) 2020-11-11
MX379817B (es) 2025-03-11
CN107735087A (zh) 2018-02-23

Similar Documents

Publication Publication Date Title
CA2984621C (en) Histone deacetylase inhibitors and compositions and methods of use thereof
CA2984618C (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US9783488B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US10106535B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US9505736B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US20160031863A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1252489B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
BR112017023711B1 (pt) Inibidores de histona deacetilase e composições e métodos de uso dos mesmos

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210419

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502